Rasagiline in Advanced Parkinson's Disease Patients With Motor Fluctuations Treated With Levodopa/Carbidopa Therapy.
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to look at the effectiveness, tolerability and safety of two doses of Rasagiline (0.5
mg and 1mg) in advanced Parkinson's Disease (PD) Patients who have been treated with
Levodopa/Carbidopa therapy.
Phase:
Phase 3
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries